Tapinarof for Psoriasis and Atopic Dermatitis: 15 Years of Clinical Research.
Robert BissonnetteE Saint-Cyr ProulxC JackC MaariPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Tapinarof is a topical, aryl-hydrocarbon receptor agonist that has recently received FDA-approval for the treatment of psoriasis. This novel therapeutic has also been shown to be effective for atopic dermatitis and is currently in phase 3 for this indication. Beyond good efficacy and fast onset of action in patients with psoriasis, the clinical response to tapinarof is notable for durable remission or near remission, maintained for an average of 130 days beyond treatment discontinuation in patients with psoriasis in phase 3 studies. Tapinarof is usually well tolerated but can induce a follicular inflammatory reaction and dermatitis in some patients. This narrative review covers the historical development of this molecule, safety and efficacy data from clinical trials conducted with various topical formulations, and practical considerations derived from our 15 years of clinical trial experience with the drug.
Keyphrases
- atopic dermatitis
- clinical trial
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- prognostic factors
- peritoneal dialysis
- electronic health record
- disease activity
- double blind
- machine learning
- deep learning
- big data
- smoking cessation
- artificial intelligence
- adverse drug
- patient reported outcomes